Understanding how the STK25 kinase helps control tumor growth
Official title: Defining the tumor suppressive mechanism of the kinase STK25
Funded at Boston University Medical Campus · NIH-11015784 · Data updated 2026-11-12
This study is looking at how a protein called STK25 helps control cell growth and prevent tumors by interacting with important pathways in our cells, and it could lead to new ways to treat cancer for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 17, 2024 |
| Project end | January 16, 2026 |
| Funding year | 2025 |
| Award (this year) | $49,538 |
| NIH project number | 5F31CA278588-02 |
| Project ID | NIH-11015784 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research are individuals diagnosed with cancers, particularly those related to dysregulation of the mTOR and Hippo pathways.
✕Less likely to help
Patients with non-cancerous conditions or those whose tumors are not influenced by the mTOR or Hippo pathways may not receive any benefit from this research.
What this research studies
This research investigates the role of the STK25 kinase in regulating cell growth and tumor suppression by examining its interactions with two important signaling pathways: mTOR and Hippo. The study aims to uncover how STK25 influences these pathways to prevent abnormal cell proliferation and tumor development. By using advanced techniques, the researchers will explore the mechanisms through which STK25 affects mTOR signaling, which is crucial for maintaining cellular balance. Patients may benefit from insights gained about tumor growth regulation and potential new therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for cancer treatment by enhancing our understanding of tumor suppression mechanisms.
How similar studies have gone: Previous research has shown promising results in understanding the roles of mTOR and Hippo pathways in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Ho, Rachel Xi-Yeen — Boston University Medical Campus
- Study coordinator: Ho, Rachel Xi-Yeen
Related research
Other NIH-funded projects on the same topics.
-
Creating a detailed map of early lung cancer changes
This study is looking at early changes in lung tissue that can lead to cancer, specifically focusing on common types of lung cancer, and it's for patients who want to help researchers understand these changes better so they can improve early detection and treatment.
-
Telomere trouble in ALT cancers: what causes damage and how it happens
Researchers are studying why some cancer cells use ALT to lengthen telomeres and how replication stress damages telomeres, aiming to uncover key processes that could be targeted in patients.
-
IL-6 signaling, lung injury, and post-TB lung disease in TB/HIV
This grant tests how a specific immune signal (IL-6) relates to lung damage after tuberculosis in people with and without HIV, aiming to understand who is at risk for lasting lung problems.
-
IL-6 signaling and lung injury after TB and HIV co-infection
This project looks at how a common immune signal called IL-6 relates to lung injury after TB treatment, especially in people who also have HIV.
-
LEAD Africa: advancing Alzheimer’s research across Africa
A new project aims to build Alzheimer’s disease research capabilities in Africa to improve understanding and care for people with dementia.
-
Leading AD and related dementias research in Africa
A multi-country effort aims to build Africa’s capacity to study Alzheimer’s disease and related dementias using scalable, low-cost methods.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.